A Novel Liquid Biopsy (NETest) identifies Paragangliomas and Pheochromocytomas with High Accuracy
Pheochromocytomas and paragangliomas (PHEOs/PGLs) represent diagnostically challenging and complex neuroendocrine tumors (NETs). Current biomarker tests for PHEOs/PGLs are technically complex or limited. We assessed the diagnostic utility of a NET-specific 51-marker gene blood assay (NETest) in patients with PHEOs/PGLs (n=81), including 10 pediatric patients, and age-/gender-matched controls (n=142) using a prospective case:control (1:2) analysis. mRNA was measured (qPCR) and results scaled 0-100 (ULN<20). Receiver Operating Curve (ROC) and non-parametric (Mann-Whitney) were used for analyses (2-tailed). All data is presented as mean±SEM. NETest accuracy for PHEO/PGL diagnosis was 100%. PHEO/PGL scores were 70±3 versus 8.5±1 in controls (p<0.0001) and ROC analysis was 0.99±0.004 (p<0.0001). Diagnostic metrics were 94% accurate, 100% sensitive, and 92% specific. Imaging correlation with 68Ga-PET-SSA was 100%. NETest levels in PHEOs (n=26) were significantly (p<0.0001) elevated (83±4) versus 66±4 in PGLs (n=40) and mixed PHEOs/PGLs (n=5: 37±3). Adrenal-derived tumors (n=30) exhibited higher scores (76±5) than extra-adrenal-derived tumors (66±4, p<0.05). Cluster 2 tumors exhibited significantly (p=0.034) elevated NETest levels (n=4: 92±2) versus Cluster 1 tumors (n=35: 69±4). Regulatory pathway analysis identified elevated RAS-RAF, metastatic, pluripotential, neural and secretory gene cluster levels (p<0.05) in PHEOs compared to PGLs. Cluster 2 PPGLs exhibited elevated (p=0.046) levels of growth-factor signaling genes compared to cluster 1. The PHEOs/PGLs in the pediatric cohort (n=10) were all NETest-positive (81±8) and exhibited a gene expression profile spectrum analogous to adults. Circulating NET transcript analysis identifies PHEOs/PGLs with 100% efficacy and is likely to have clinical utility in the diagnosis and management of PHEO/PGL patients.